Back
Open Access

Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors

Session: Interventions to improve outcomes in cardio-oncology
Topic: Cardio-Oncology
Speaker: Doctor M. Slieman (Tel Aviv, IL)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Moaad Slieman

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)
0 follower

4 more presentations in this session

Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study

Speaker: Doctor I. Martins Moreira (Vila Real, PT)

Access
Abstract
Like
Thumbnail

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.

Speaker: Doctor S. Maragkoudakis (Chania, GR)

Access
Abstract
Like
Thumbnail

Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort

Speaker: Doctor I. Araujo (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Cardiotoxicity and immune checkpoint inhibitors: a heartfelt myth or the real deal?

Speaker: Doctor S. Esteves (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Access the full session

Interventions to improve outcomes in cardio-oncology

Speakers: Doctor M. Slieman, Doctor I. Martins Moreira, Doctor S. Maragkoudakis, Doctor I. Araujo, Doctor S. Esteves
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources